Boston Scientific (NYSE:BSX) said Tuesday that the U.K.’s National Institute for Health and Care Excellence now provides guidance supporting the use of its GreenLight XPS laser therapy system used to treat prostatic enlargement in patients with benign prostatic hyperplasia.
NICE, which provides evidence-based guidance and standards to the U.K.’s National Health Service, said that adoption of the GreenLight XPS system to treat non high-risk patients with BPH can “significantly reduce costs for the NHS,” Marlborough, Mass.-based Boston Scientific said.
“The GreenLight XPS System is a well-established treatment to help men with BPH. It is suitable for almost all men, even those who may not be deemed fit for conventional surgery. The positive guidance from NICE will give more men access to the GreenLight XPS System and may allow surgeons to treat patients on an outpatient basis, with excellent outcomes and with fewer complications,” Dr. Gordon Muir, of London’s King’s College Hospital said in a press release.
The Institute said that adoption of the system over current surgical treatment could result in savings of between $3.2 million (£2.3 million) and $4.5 million (£3.2 million) annually for the NHS.
“Using technology to improve care and lower health care costs directly benefits patients, hospitals and providers. NICE is internationally recognized for its evidence-based review process and this guidance demonstrates the importance of continually evaluating how we can make improvements in caring for patients,” Boston Scientific MedSurg prez Michael Phalen said in a prepared statement.
The new guidance from NICE came based on data from the 291-patient Goliath study. Data from the study indicated that laser therapy treatment has fewer initial serious post-procedure complications, with lower hospital re-admissions and outcomes that are “equally effective as the current standard surgical treatment,” Boston Scientific said.
In May, Boston Scientific said it won FDA approval for its Precision Montage MRI-safe spinal cord stimulator for chronic pain, and launched the device in the U.S.
The Precision Montage MRI SCS is cleared for full-body, 1.5 Tesla MRI scans, the company said. It’s designed to deliver multiple waveforms so patients can tailor their therapy as their pain evolves, and uses Boston Scientific’s IlLumina 3D algorithm to create a computer model so surgeons can target the source of the pain.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.